Forty Seven Inc (NASDAQ:FTSV) Receives $25.88 Average Price Target from Analysts

Shares of Forty Seven Inc (NASDAQ:FTSV) have received an average rating of “Buy” from the eleven research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $25.88.

Several brokerages have recently weighed in on FTSV. Zacks Investment Research cut shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. Oppenheimer set a $13.00 price target on shares of Alpine Immune Sciences and gave the stock a “buy” rating in a research note on Tuesday, March 19th. HC Wainwright set a $5.00 price target on shares of Eyepoint Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday. Guggenheim cut shares of Anadarko Petroleum from a “buy” rating to a “hold” rating and set a $69.00 price target on the stock. in a research note on Friday, April 12th. Finally, Roth Capital assumed coverage on shares of Forty Seven in a research report on Wednesday, May 29th. They set a “buy” rating and a $28.00 price objective on the stock.

Shares of Forty Seven stock traded down $0.13 on Tuesday, hitting $10.12. 117,600 shares of the company’s stock were exchanged, compared to its average volume of 189,274. The firm has a 50-day moving average of $10.86. The company has a market capitalization of $322.37 million and a PE ratio of -2.70. Forty Seven has a 1 year low of $9.76 and a 1 year high of $23.83.

Forty Seven (NASDAQ:FTSV) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.14). As a group, research analysts forecast that Forty Seven will post -2.72 EPS for the current year.

In other news, insider Mark Anthony Mccamish sold 16,500 shares of the firm’s stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $18.12, for a total transaction of $298,980.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ravindra Majeti sold 4,311 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $16.02, for a total transaction of $69,062.22. The disclosure for this sale can be found here. Insiders have sold a total of 81,811 shares of company stock worth $1,260,608 over the last 90 days. Insiders own 37.40% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its holdings in Forty Seven by 89.5% in the 4th quarter. BlackRock Inc. now owns 845,954 shares of the company’s stock valued at $13,298,000 after acquiring an additional 399,591 shares during the last quarter. Candriam Luxembourg S.C.A. increased its holdings in Forty Seven by 500.0% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 120,000 shares of the company’s stock valued at $1,939,000 after acquiring an additional 100,000 shares during the last quarter. Northern Trust Corp increased its holdings in Forty Seven by 388.3% in the 4th quarter. Northern Trust Corp now owns 88,769 shares of the company’s stock valued at $1,396,000 after acquiring an additional 70,591 shares during the last quarter. Geode Capital Management LLC increased its holdings in Forty Seven by 103.0% in the 4th quarter. Geode Capital Management LLC now owns 88,165 shares of the company’s stock valued at $1,385,000 after acquiring an additional 44,735 shares during the last quarter. Finally, Exane Asset Management increased its holdings in Forty Seven by 148.1% in the 1st quarter. Exane Asset Management now owns 67,000 shares of the company’s stock valued at $1,083,000 after acquiring an additional 40,000 shares during the last quarter. Hedge funds and other institutional investors own 47.34% of the company’s stock.

Forty Seven Company Profile

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Read More: Why is a lock-up period needed for an IPO?

Analyst Recommendations for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.